# Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635
Ticker: ALNY
Company: Alnylam Pharmaceuticals, Inc.
Source: Alnylam Pharmaceuticals, Inc.
Published: 2026-07-16 12:00 EST
Original Source URL: https://investors.alnylam.com/press-releases
## Summary

Jul 16, 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial res...

## Article Body
Jul 16, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open.

Management will provide an update on the Company and discuss second quarter 2026 results as well as expectations for the future via conference call on Thursday, July 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events . An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X , LinkedIn , Facebook , Instagram , or YouTube .

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716457592/en/

Alnylam Pharmaceuticals, Inc. Bo Piela

(Media)

508-308-9783

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.
## Recent Company News
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-15 12:00 EST — [Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurologi](https://biopharmsignal.com/news/ALNY/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-showcasing-p-508fc61d) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:25 EST — [Alnylam to Webcast Presentations at Upcoming Investor Conferences](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-presentations-at-upcoming-investor-conferences-50fb6676) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:25 EST — [New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutris](https://biopharmsignal.com/news/ALNY/new-data-analyses-presented-at-heart-failure-2026-demonstrate-robust-and-consist-d10768e9) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — [Alnylam Issues 2025 Corporate Responsibility Report](https://biopharmsignal.com/news/ALNY/alnylam-issues-2025-corporate-responsibility-report-62023cfe) — Source: Alnylam Pharmaceuticals, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)